Skip to content

Effect of MS in Stomach Discomport Symptoms and Hangover relief for the Efficacy and Safety; Controlled Clinical Trial

Effect of MS in Gastrointestinal Symptoms and Hangover relief for the Efficacy and Safety; Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003898
Enrollment
24
Registered
2019-05-08
Start date
2018-07-13
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : MS, 500mg/day, once a day, oral administration, 12 subjects of 24 subjects intake of MS and other intake Placebo. After 2 weeks, subjects intake vice versa for single intake of M

Sponsors

ChongKunDang Healthcare
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) A person who has had a alcoholic intoxification experience after drinking 2) One or more of the following symptoms (If symptoms start before 6 months and have been experiencing them for the past 3 months) - Bothersome postprandial fullness - Bothersome early satiation - Bothersome epigastric pain - Bothersome epigastric burning 3) A person who agrees to participate in this human body application test and has written consent

Exclusion criteria

Exclusion criteria: Except for those who fall under one or more of the following conditions, they are subjected to the human body application test. 1) A person with severe malignant tumors, cerebrovascular diseases (cerebral infarction, cerebral hemorrhage, etc.), and cardiac diseases (cardiac infarction, cardiac arrest, heart failure, and arrhythmia, which may require treatment) 2) Peptic ulcer and reflux esophagitis patient 3) A person who has had surgery to suppress the secretion of gastric acid or surgery to the stomach 4) Alcoholics Anonymous or Alcoholics 5) A person who has drunk enough to cause disruptions to the test within one week of starting the test 6) A person who constantly takes NSAID(NonSetroidal Anti-inflammatory drugs), NSAIDs, and painkillers 7) A person who has taken medication or health function food related to liver function improvement within two weeks of starting test 8) A person with liver function defect through drug and history investigation 9) A person who experiences new error through medication and medical history 10) A person with thyroid disease 11) Unadjusted hypertension patient (measured after 10 minutes of stabilization of test subjects) 12) Diabetes patients who can not control their blood sugar levels through medication and medical history 13) A person who is pregnant or has a pregnancy plan during this human body application test 14) A person who has participated in another clinical trial within one month or plans to participate in another clinical trial during this human body application test

Design outcomes

Primary

MeasureTime frame
Blood alcohol (blood, exhalation), acetaldehyde concentration;Stomach symptom score, Alcohol intoxication score;Blood ILs (IL-6,IL-10?) concentration

Secondary

MeasureTime frame
Blood pressure, pulse, weight

Countries

Korea, Republic of

Contacts

Public ContactYe-Rin Lee

CHA University

2yealin@naver.com+82-2-000-0000

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026